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Introduction
•  Myelodysplastic Syndrome (MDS) is a group of 
disorders characterized by
   abnormal myeloid maturation resulting in 
peripheral cytopenia and bone marrow 
dysplasia. 
   MDS with excess blasts (MDS-EB) is defined 
as presence of 5-19% of blasts in the 
peripheral blood or bone marrow and may 
progress to AML with blast percentage >20%. 
•  Sweet Syndrome (SS) is a rare inflammatory 
skin condition that can be secondary to 
chemotherapy or the underlying malignancy 
   associated with AML and MDS in adults, 
however, is particularly rare in children.  
   pathophysiology is thought to include 
hypersensitivity reactions, cytokine 
dysregulation especially G-CSF and genetic 
susceptibility to the disease process. 
•  Major diagnostic criteria include 
   abrupt onset of painful erythematous 
plaques/nodules 
   histopathologic evidence of sterile 
neutrophilic panniculitis. 
•  Minor criteria include 
   excellent response to steroids,
   underlying malignancy 
   three of the following: ESR >20 mm/hr,  
CRP, >8,000 leukocytes and  
>70 percent neutrophils.
Case Report
•  We present a case of a 4-year-old male with SS associated with MDS-EB 
undergoing chemotherapy.
•  Patient had previously failed therapy with Azacytidine now admitted for 
bridge chemotherapy with cytarabine and Erwinia L-asparaginase as per 
modified AAML1031. 
•  Despite morphine, pain associated with these lesions worsened, hindering 
ambulation. He had similar nodules during previous induction cycles 
starting around his ANC nadir.  
•  A biopsy showed patchy predominant lobular neutrophilic panniculitis and 
focal neutrophilic folliculitis without malignant infiltration.
Discussion
•  Laboratory results remarkable for ESR 67, CRP 
302, ferritin 1,398. 
•  These above findings and the patient’s clinical 
presentation course supported the clinical 
diagnosis of SS. 
•  Given his immunosuppressive status, steroid 
treatment was deferred. 
•  Patient was treated with ketorolac and 
supportive care, and the lesions and pain 
gradually improved as his ANC counts 
recovered with a similar pattern to prior cycles.
Conclusion
•  This atypical presentation of SS presents the 
first case report of a pediatric patient with SS 
secondary to MDS-EB. 
•  An abnormal response in this patient’s 
endogenous G-CSF production for promoting 
bone marrow recovery is proposed to be the 
trigger that led to development of SS. 
•  This response observed with anti-inflammatory 
treatment poses the possibility of considering 
this treatment as an alternative for pain control 
during the peak of immunosuppressive state 
while undergoing chemotherapy. 
